Jane Street Group LLC Sells 20,552 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Jane Street Group LLC decreased its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 16.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 107,572 shares of the company’s stock after selling 20,552 shares during the period. Jane Street Group LLC owned 0.05% of Taysha Gene Therapies worth $216,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TSHA. Bank of New York Mellon Corp acquired a new stake in Taysha Gene Therapies during the 2nd quarter worth $1,018,000. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies in the 2nd quarter worth $48,000. Rhumbline Advisers acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth $413,000. The Manufacturers Life Insurance Company increased its holdings in Taysha Gene Therapies by 109.0% in the second quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock valued at $298,000 after purchasing an additional 69,487 shares during the last quarter. Finally, Scientech Research LLC acquired a new position in Taysha Gene Therapies in the second quarter valued at about $97,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TSHA. Canaccord Genuity Group boosted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Chardan Capital restated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a report on Monday, January 6th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Trading Down 8.8 %

TSHA opened at $1.76 on Monday. The stock has a market capitalization of $360.70 million, a P/E ratio of 2.79 and a beta of 0.95. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 12 month low of $1.19 and a 12 month high of $4.32. The firm’s fifty day simple moving average is $2.11 and its 200 day simple moving average is $2.13.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.